Pages that link to "Q39912133"

The following pages link to The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. (Q39912133):

Displaying 20 items.

• Profile of veliparib and its potential in the treatment of solid tumors (Q26801272) (← links)
• Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer (Q33414863) (← links)
• Bioenergetic metabolites regulate base excision repair-dependent cell death in response to DNA damage (Q33598840) (← links)
• Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation (Q34146866) (← links)
• Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. (Q34300803) (← links)
• Mechanisms and insights into drug resistance in cancer (Q36682301) (← links)
• Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma (Q36887663) (← links)
• Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer (Q37237962) (← links)
• Tripartite Motif-containing 33 (TRIM33) protein functions in the poly(ADP-ribose) polymerase (PARP)-dependent DNA damage response through interaction with Amplified in Liver Cancer 1 (ALC1) protein (Q37289213) (← links)
• PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. (Q40640808) (← links)
• Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors (Q41276800) (← links)
• Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics (Q41850697) (← links)
• Early human studies of investigational agents: dose or microdose? (Q41896620) (← links)
• Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry (Q42604869) (← links)
• Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy. (Q52604402) (← links)
• Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent. (Q55457376) (← links)
• PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity (Q61811738) (← links)
• Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness (Q90040642) (← links)
• A critical evaluation of methods to interpret drug combinations (Q90546452) (← links)
• Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias (Q93230457) (← links)